Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

NCT07486817 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Non-squamous, Non-small Cell

Interventions

DRUG: Zongertinib
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Pembrolizumab

Sponsor

Boehringer Ingelheim